Baskin Britahny M, Dwoskin Linda P, Kantak Kathleen M
Department of Psychological and Brain Sciences, Boston University, Boston, MA 02215, USA..
Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536 USA.
Pharmacol Biochem Behav. 2015 Apr;131:51-6. doi: 10.1016/j.pbb.2015.01.019. Epub 2015 Jan 31.
Past research with the spontaneously hypertensive rat (SHR) model of attention deficit/hyperactivity disorder showed that adolescent methylphenidate treatment enhanced cocaine abuse risk in SHR during adulthood. The acquisition of cocaine self-administration was faster, and cocaine dose-response functions were shifted upward under fixed-ratio and progressive ratio schedules compared to adult SHR that received adolescent vehicle treatment or to control strains that received adolescent methylphenidate treatment. The current study determined if extending treatment beyond adolescence would ameliorate long-term consequences of adolescent methylphenidate treatment on cocaine abuse risk in adult SHR. Treatments (vehicle or 1.5mg/kg/day oral methylphenidate) began on postnatal day 28. Groups of male SHR were treated with vehicle during adolescence and adulthood, with methylphenidate during adolescence and vehicle during adulthood, or with methylphenidate during adolescence and adulthood. The group receiving adolescent-only methylphenidate was switched to vehicle on P56. Cocaine self-administration began on postnatal day 77, and groups receiving methylphenidate during adolescence and adulthood were treated either 1-h before or 1-h after daily sessions. At baseline under a fixed-ratio 1 schedule, cocaine self-administration (2h sessions; 0.3mg/kg unit dose) did not differ among the four treatment groups. Under a progressive ratio schedule (4.5h maximum session length; 0.01-1.0mg/kg unit doses), breakpoints for self-administered cocaine in SHR receiving the adult methylphenidate treatment 1-h pre-session were not different from the vehicle control group. However, compared to the vehicle control group, breakpoints for self-administered cocaine at the 0.3 and 1.0mg/kg unit doses were greater in adult SHR that received adolescent-only methylphenidate or received methylphenidate that was continued into adulthood and administered 1-h post-session. These findings suggest that extending methylphenidate treatment beyond adolescence does not ameliorate explicitly the long-term consequences of adolescent methylphenidate treatment. Pre-session methylphenidate may mask temporarily the detection of an increase in cocaine self-administration following chronic methylphenidate treatment.
过去对注意力缺陷多动障碍的自发性高血压大鼠(SHR)模型的研究表明,青少年期使用哌甲酯治疗会增加成年SHR滥用可卡因的风险。与接受青少年期赋形剂治疗的成年SHR或接受青少年期哌甲酯治疗的对照品系相比,在固定比率和累进比率给药方案下,可卡因自我给药的习得更快,且可卡因剂量反应函数向上偏移。当前研究确定,将治疗延长至青少年期之后是否会改善青少年期哌甲酯治疗对成年SHR滥用可卡因风险的长期影响。治疗(赋形剂或1.5mg/kg/天口服哌甲酯)从出生后第28天开始。雄性SHR组在青少年期和成年期接受赋形剂治疗,或在青少年期接受哌甲酯治疗而在成年期接受赋形剂治疗,或在青少年期和成年期均接受哌甲酯治疗。仅在青少年期接受哌甲酯治疗的组在出生后第56天改为接受赋形剂治疗。可卡因自我给药从出生后第77天开始,在青少年期和成年期接受哌甲酯治疗的组在每日给药前1小时或给药后1小时接受治疗。在固定比率1给药方案的基线条件下,四个治疗组之间的可卡因自我给药(2小时给药期;0.3mg/kg单位剂量)没有差异。在累进比率给药方案下(最长给药期4.5小时;0.01 - 1.0mg/kg单位剂量),在给药前1小时接受成年期哌甲酯治疗的SHR中,自我给药可卡因的断点与赋形剂对照组没有差异。然而,与赋形剂对照组相比,在0.3和1.0mg/kg单位剂量下,仅在青少年期接受哌甲酯治疗或在成年期继续接受哌甲酯治疗且在给药后1小时给药的成年SHR中,自我给药可卡因的断点更高。这些发现表明,将哌甲酯治疗延长至青少年期之后并不能明确改善青少年期哌甲酯治疗的长期影响。给药前使用哌甲酯可能会暂时掩盖长期使用哌甲酯治疗后可卡因自我给药增加的检测。